

5000

#6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEST AVAILABLE COPY

Attorney Docket No.: DEX-0184

Inventors: Roberto A. Macina

Serial No.: 09/806,311

Filing Date: Not yet assigned

Examiner: Not yet assigned

Group Art Unit: Not yet assigned

Title: A Novel Method of Diagnosing,
Monitoring, Staging, Imaging and
Treating Gastrointestinal Cancers

I, Kathleen A. Tyrrell, Registration No. 38,350, certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On this date: November 14, 2001



Kathleen A. Tyrrell, Registration No. 38,350

Commissioner for Patents
BOX PCT
United States Patent and Trademark Office
Washington, DC 20231

Sir:

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

In response to the "Notification of Defective Response"
dated October 19, 2001, a response to which is due November 19,
2001, enclosed herewith is:

- (XX) Amendment under 1.825;
- (XX) Statement to Support Filing and Submission in Accordance with 37 CFR §§1.821 through 1.825;
- () Substitute pages of the Sequence Listing;

Substitute copy of the computer readable form of Sequence Listing;


Copy of Notification of Defective Response;

Petition for Three (3) Month Extension of Time;

Other: _____

The Commissioner is hereby authorized to charge any underpayment associated with this communication or credit any overpayment to Deposit Account No. 50-1619. This sheet is attached in duplicate.

Respectfully submitted,



Kathleen A. Tyrrell
Registration No. 38,350

Date: November 14, 2001

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

H.6
PCT/PTO 22 JAN 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0184

Inventors: Roberto A. Macina

Serial No.: 09/806,311

Filing Date: Not yet assigned

Examiner: Not yet assigned

Group Art Unit: Not yet assigned

Title: A Novel Method of Diagnosing,
Monitoring, Staging, Imaging and
Treating Gastrointestinal Cancers

I, Kathleen A. Tyrrell, Registration No. 38,350, certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On this date: November 14, 2001


Kathleen A. Tyrrell, Registration No. 38,350

Commissioner for Patents
BOX PCT
United States Patent and Trademark Office
Washington, DC 20231


Sir:

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825

- () I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
- () I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
- () I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.

- () I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing were made to conform with the current Sequence Listing rules. I hereby state that the substitute sheet(s) of the Sequence Listing does not include new matter.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing submitted herewith.
- (XX) I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), contains identical data to that originally filed.

Respectfully submitted,



Kathleen A. Tyrrell
Registration No. 38,350

Date: November 14, 2001

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Commissioner For Patents, Box PCT, United States Patent and Trademark Office, Washington, D.C. 20231, www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/806,311	Roberto A Macina	DEX-0184

Licata & Tyrrell
66 East Main Street
Marlton, NJ 08053

Docket System ✓
Status Report ✓
Docket Book ✓

INTERNATIONAL APPLICATION NO.

PCT/US99/22725

I.A. FILING DATE	PRIORITY DATE
09/30/1999	10/02/1998

CONFIRMATION NO. 8561

371 FORMALITIES LETTER



OC000000006921900

Notice to Comply

Date Mailed: 10/19/2001

11/19/01
MAX 4/19/02

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Oath or Declaration

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
 - The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
 - **APPLICANT MUST PROVIDE:**
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended up to a maximum of six months.

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

VONDA M WALLACE

Telephone: (703) 305-3736

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/806,311	PCT/US99/22725	DEX-0184